Breaking News: Gilead Sciences Halts Six Idelalisib Combination Trials After serious adverse events were reported in patients, Gilead Sciences, Inc. has halted six clinical trials using idelalisib in combination with other drugs. The trials were in the process of investigating use of the drug in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and indolent non-Hodgkin lymphomas (NHL). Leading expert Dr. Jeff Sharman joins Patient Power to explain what happened and what it could mean for patients. Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter | Follow on Google+ |